Where does Rhizen Pharmaceuticals AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rhizen Pharmaceuticals AG ranks #6,587 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rhizen Pharmaceuticals AG hold?

Rhizen Pharmaceuticals AG holds 51 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Rhizen Pharmaceuticals AG's Innovation Score?

Rhizen Pharmaceuticals AG has an Innovation Score of 38.1 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Rhizen Pharmaceuticals AG focus on?

Rhizen Pharmaceuticals AG's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 49 patents, ranking #367 of 6,058 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Rhizen Pharmaceuticals AG's patent grant rate increasing or decreasing?

Rhizen Pharmaceuticals AG's recent grant velocity is -44% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Rhizen Pharmaceuticals AG's patents?

Rhizen Pharmaceuticals AG's patents average 19.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rhizen Pharmaceuticals AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Rhizen Pharmaceuticals AG

USPTO PatentsView assignee record - 51 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Rhizen ranks #6,587 of 49,997 tracked US assignees by granted-patent volume, with 51 patents across 11 technology areas.

#6,587
of 49,997 US assignees by volume: Top 42%
by Innovation Score (38.1/100): 19.2
avg claims per patent: -44%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6587 · Foreign Corporation #6,587 · 51 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 51 grants
UPPER-Q #6,587/49,997
PHOTO-FINISH Optum Technology
CPC-FOCUS A61P · 11 areas
INNOV-THIN 38.1/100
CLAIMS-RICH 19.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -44% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Optum Technology, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Rhizen’s 38.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.6 pts (36%) Velocity 1.2 pts (3%) Breadth 11.7 pts (31%) Claim depth 11.5 pts (30%)

Qualcomm Incorporated · highest

85
Cavendish Kinetics · near

38
Epic Games · near

38
Ipar · near

38
Rhizen Pharmaceuticals · this assignee

38
Sonendo · near

38
3D Lighting… · lowest

7

What this shows Rhizen's Innovation Score is 38.1/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Rhizen?

Each dot is one of Rhizen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rhizen’s own 19.2 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Rhizen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Rhizen's grants concentrate

Rhizen Pharmaceuticals AG is a focused PatentsView assignee: 11 CPC subclasses with 96.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (11 grants) versus a trough of 1 in 2024. By volume, Rhizen sits between Optum Technology, Inc. and Shandong Linglong Tire Co., Ltd.

Rhizen's three-year grant acceleration

From 2019–2021 to 2022–2024, Rhizen Pharmaceuticals AG moved from 22 to 4 grants (0.18x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Optum Technology

51
Paraty B V B A

51
Polyvalor Partner…

51
Proslide Technolo…

51
Rafael Advanced D…

51
Reservoir Labs

51
S&P Global

51
Shandong Linglong…

51
Rhizen Pharmaceut… ◀

51

What this shows Rhizen holds 51 patents at rank #6,585, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rhizen

By rank, the assignees closest to #6,585 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Rhizen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Rhizen, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Rhizen ranks #367 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Cavendish Kinetics, Inc. 38 Sonendo, Inc. 38 Ipar, LLC 38 Epic Games, Inc. 38

Similar claim depth

Nearest assignees by average claims per patent (19.2 here).

NUtech Ventures 19.2 avg Landmark Graphics Corporation 19.2 avg Phytogen Seed Company, LLC 19.2 avg Keysight Technologies Singapore (HOLDINGS) PTE. Ltd. 19.2 avg

Rhizen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Rhizen Pharmaceuticals AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	7.8%
2016	3	5.9%
2017	11	21.6%
2018	6	11.8%
2019	8	15.7%
2020	8	15.7%
2021	6	11.8%
2022	3	5.9%
2024	1	2.0%
2025partial year	1	2.0%

Which technologies does Rhizen Pharmaceuticals AG patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 49

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 48

C07D - Heterocyclic Compounds 43

Y02A - Technologies FOR Adaptation TO Climate Change 28

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

C07C - Acyclic OR Carbocyclic Compounds 6

C12Y - Enzymes 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 5

C07K - Peptides 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Rhizen Pharmaceuticals AG's patent record in context - here's where to go next.

Rhizen Pharmaceuticals AG's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 96.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,587 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Rhizen Pharmaceuticals AG against Optum Technology, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.